AOD-9604
ResearchAOD-9604 (HGH Fragment 176-191)
- Category
- Weight Loss & Metabolism
- Aliases
- HGH Fragment 176-191, Anti-Obesity Drug 9604
- Administration
- Subcutaneous injection
Timing
A general projection of what people report noticing over time, based on the known mechanism and reported use patterns. It is not a guarantee and individual experience varies considerably.
- 1
1–2 Weeks
Most users do not report a distinct early sensation, consistent with trial results showing limited effect versus placebo.
- 2
3–4 Weeks
Any fat-loss-related sensation tends to be subtle, if present at all.
- 3
5–7 Weeks
Continued use has not been shown to produce a clearly felt difference in available research.
- 4
8–10 Weeks
Users generally do not report a strong distinguishing sensation at this stage.
- 5
11–15 Weeks
Available evidence does not support expecting a pronounced felt effect through this window.
- 6
16–20 Weeks
Any changes reported by users during this period are difficult to distinguish from diet and exercise alone.
- 7
21–24 Weeks
By this stage, most users evaluating this compound rely on measured outcomes rather than felt sensation, given the mixed clinical evidence.
⚠️ Research context only. This is not medical advice and results are not guaranteed.